Pavel is an MRC Investigator (Programme Leader Track) and NIHR Fellow working on the development and implementation of adaptive designs in clinical trials. He provides statistical support in a number of academic clinical trials and consults pharmaceutical companies on the development of novel adaptive designs and supports their implementations in real trials.

Ayon is the Head of Biostatistics, India at Eli Lilly and is managing a group of 40 Biostatisticians in multiple therapeutic areas. He is an expert in the field of adaptive designs in clinical trials and has been actively contributing to the field of Covariate-Adjusted Response Adaptive Randomization for survival trials and Dose Optimization methods in early phase oncology through multiple cross industry collaborations. He is a Chartered Statistician from the Royal Statistical Society and in also involved in supervising multiple PhD students in the field of Adaptive Randomization and Dose Optimization Trials.

Dr. Gina D’Angelo is a Director at AstraZeneca Oncology Statistical Innovation, and offers her guidance and statistical expertise on early-late clinical trials. She has over 20 years of academic and industry experience on preclinical and clinical trials with an emphasis on dose-finding, biomarkers, and study design. She received a PhD in Biostatistics from University of Pittsburgh and was faculty in the Biostatistics Division at Washington University in St. Louis. She is co-authoring a book chapter on dose optimization and co-editing a book on statistical and design consideration for biomarkers in clinical trials. Her experience spans from discovery to late phase trials, with small to high-dimensional data, across various therapeutic areas.

Dr. Michael Sweeting is the Director of Statistical Innovation in Oncology Biometrics at AstraZeneca, with over two decades of extensive research and management experience in Biostatistics. His expertise spans early and late-phase trial design, real-world evidence (RWE), observational data analysis, Health Technology Assessment (HTA), simulation, and software development. Michael is dedicated to advancing innovative statistical research and leadership within drug development and reimbursement and is committed to creating tools and training materials to facilitate the implementation of new statistical methods.
Before joining AstraZeneca, Michael served as an Associate Professor at the University of Leicester and a Senior Researcher at the University of Cambridge. There, he was the lead statistician on several high-profile cancer and cardiovascular research programs. He has published in both substantive and methodological areas of research, with an h-index of 64, over 250 peer-reviewed publications, and more than 15,000 citations.

Anaïs Andrillon is a Statistical Methodologist at Saryga, a company dedicated to support innovation in statistics and decision-making in healthcare. Jointly with her colleagues, she assists pharmaceutical companies, and biotechnology companies on developing and using advanced statistical methodologies to optimize drug development plans and clinical trials. With an active collaboration with academia, Saryga also contributes to the research and the publication of novel approaches. Anaïs holds a PhD in Biostatistics from Université Paris Cité on adaptive dose-finding designs in oncology.